Does transcatheter leaflet approximation (TMVr) reduce death and HF hospitalization in heart failure patients with 3+ or 4+ secondary mitral regurgitation?
Strict application of COAPT echocardiographic criteria enables the translation of TMVr benefits (reduced death and HF hospitalization) to clinical practice for patients with secondary mitral regurgitation.
HF patients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation The COAPT Trial COAPT; NCT01626079).
Asch et al. (2019) studied this question.